ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

IN-207907 120 mg

Also written as “IN-207907 240 mg” and “IN-207907 360 mg”.

Its studies are mostly in Sarcopenia, led by HK inno.N.

Furthest: phase 2, since Jun 16, 20261 company-led study, 1 open or runningNext primary completion: Feb 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HK inno.N11 open or runningphase 2since Jun 16, 2026Jun 16, 2026Feb 2028phase 2 · NCT07668180

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 16, 2026First study: phase 2 study in Sarcopenia in ElderlyFirst studyNCT07668180 · 100 planned

Ahead

  1. Feb 2028Primary completion: phase 2 study in Sarcopenia in ElderlyNCT07668180

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07668180Sarcopenia in Elderly2Not yet recruitingFeb 2028100

How it is read

Names in the registry

  • “IN-207907 120 mg”, 1 entry
  • “IN-207907 240 mg”, 1 entry
  • “IN-207907 360 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.